EFFECT OF CANDESARTAN ON PARAMETERS OFDAILYBLOOD PRESSURE IN PATIENTS WITH CHRONIC KIDNEYDISEASE ON HEMODIALYSIS

V. A. Vizir; О. G. Ovska; A. S. Sadomov

doi:10.31450/ukrjnd.3(43).2014.05

V. A. Vizir Zaporizhzhya State Medical University
О. G. Ovska Запорізький державний медичний університет
A. S. Sadomov Zaporizhzhya State Medical University

DOI: https://doi.org/10.31450/ukrjnd.3(43).2014.05

Keywords: chronic renal disease, hemodialysis, ambulatory bloodpressure monitoring, arterial hypertension, candesartan.

Abstract

Introduce.Advances of normal blood pressure in patients on program hemodialysis presented a serious problem related disciplines. For verification hypertension used routine blood pressure measurement and ambulatory monitoring to control the pressure in interdialytic time, which is an important predictor of cardiovascular events among these patients.

The aim of research was to investigate features ofparameters the ambulatory monitoring of blood pressure in the dynamics after treatment of candesartan in patients receiving renal replacement therapy.

Materials and methods: 53patients ongoing chronic hemodialysis were makethe ambulatory monitoring of blood pressure before and after 12–weeks treatment of candesartan (4–32 mg).

Results. It was established that the prevalence of hypertension in a population of patients on hemodialysis influenced by candesartan treatment decreased from 53.6 % to 32.1 %. Patients on hemodialysis in 75 % of cases have incresedpulse pressure (> 60 mm Hg), the percentage of which after therapy decreased to 51.8. Prevailing type of daily blood pressure as the treatment and after treatment is «non–dipper». Established that candesartan showed a positive effect in relation to a statistically significant reduction in the average time indices and blood pressure

Conclusion: results of the study allowtorecommend candesartan for treatment of hypertension in hemodialysis patients.

Downloads

Download data is not yet available.

References

Пьянкина О. В. Влияние уремических факторов на процессы ремоделирования периферических сосудов у больных хронической болезнью почек / О. В. Пьянкина, П. Б. Татаринцев , О. Н. Рагозин // Современные проблемы науки и образования. – 2013. – №1. Режим доступу до журналу: http://www.science–education.ru/107–r8509.

Уніфікований клінічний протокол «Лікування пацієнтів з хронічною хворобою нирок V Д стадії: профілактика, діагностика та лікування серцево– судинних захворювань», Київ, 2011, –17 с.

AgarwalR. Managing hypertension using home blood– pressure monitoring among haemodialysis patients–a call to action / Rajiv Agarwal // J Nephrol Dial Transpl. – 2010– V. 25(6).– P. 1766–1771.

Agarwal R. Volume–associated ambulatory blood pressure patterns in hemodialysis patients/ Rajiv Agarwal // Hypertension. – 2009. –V. 54. –Р. 241–247.

Barra S. Vascular and metabolic effect sofangiotensin II receptor blockers / Barra S., Vitagliano A., Cuomo V. [et al]// ExpertOpin. Pharmacother.– 2009 – V. 10, № 2. –P. 173–189.

Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension / Heran B.S., Wong M. M. Y., Heran I. K. [etal] // The Cochrane Library. – 2009. – V. 4. – P. 1–152.

Canadian Hypertension Education Program Out comes Research Taskforce. Antihypertensived rugpersistence and compliance among new lytreatedelderly hypertensives in Ontario / Friedman O., Mc Alister F.A., Yun L. [etal] // Am. J. Med. – 2010. – V. 123, №2. –P. 173–181.

Cardiovascular disease in chronic renalfailure: the challenge continues/ Locatelli F., Maralli D., Conte F. [etal] // Nephrol.Dial.Transpl. – 2000.– P. 69–80.

Effects of angiotensin receptor blockers on cardiovascular events in patients under going hemodialysis: an open–label randomized controlled trial/ SuzukiH, KannoY, SugaharaS [etal] // Am J Kidney Dis. – 2008.–V. 52, № 3.– Р. 400–402.

Effect of lowering blood pressure on cardiovascularevents and mortality in patient sondialysis: a systematic review and meta–analysis of randomised controlled trials / Heerspink H. J., Ninomiya T., Zoungas S. [et.al] // Lancet. – 2009. –V. 373. –P. 1009–1015.

ESH/ESC Guide lines for the management of arterial hypertension 2013.

Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients / Agarwal R., Andersen M. J., Bishu K. [etal] // KidneyInt. – 2006. – V. 69. – P. 900–906.

KDIGO Clinical Practice Guide line for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Intsuppl. – 2012.–V. 2, № 5. – P. 336–415. Режим доступу: http://www.kidney–international.org).

Medical options to fight mortality in end–stage renal disease: a review of the literature / RafaelKramann, JürgenFloege, MarkusKetteler [etal] // Nephrol. Dial. Transplant. –2012. – V. 27, № 12. – Р. 4298–4307.

National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Cardiovascular Diseasein Dialysis. Am J Kidney Dis. – 2005. – № 45. – P.1– 153.

Noimpact of hyperkalaemia with renin–angiotensin system blockadesinmaintenance haemodialysis patients / Sang–WoongHan, Young–WoongWon, Joo–HarkYi, andHo–JungKim // Nephrol. Dial. Transplant. – 2007. –V. 22, № 4. –P. 1150–1155.

Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS / AntonioAlbertoLopes, Jennifer L. Bragg– Gresham, SylviaP. B. Ramirez [etal] // Nephrol. Dial. Transplant. – 2009. – V. 24, № 9. – Р. 2809–2816.

SinhaA. D. Peridialytic, intradialytic, and interdialytic blood pressure measurement in hemodialysis patients / Sinha A. D. , Agarwal R. // Am J KidneyDis. – 2009. –V. 54. – P. 788–791.

Tomson C. R. Blood pressure and out come in patients on dialysis / Tomson C. R // Lancet. – 2009. – V.373. –P. 981–998.

Walter H. H rl. Hypertension in end–stage renal disease: different measures and the irprognostic significance / Walter H. Horl// J Nephrol Dial Transpl. – 2010. –V. 25, № 10.–P. 3161–3166.